Developing a new vaccine approach to target HIV-1
mRNA-based chimeric membrane protein vaccination strategies directed at the MPER
This study is testing a new vaccine designed to help your body fight HIV by teaching it to recognize and respond to the virus better, and people living with HIV may have the chance to participate in trials to see how well it works and if it's safe.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11062378 on NIH RePORTER |
What this research studies
This research focuses on creating a vaccine that can effectively induce broadly neutralizing antibodies (bnAbs) against the HIV-1 virus. It aims to overcome challenges posed by the virus's ability to change its structure and evade the immune response. The approach involves designing immunogens that mimic the virus's protective features, allowing the immune system to better recognize and respond to the virus. Patients may be involved in trials to test the safety and effectiveness of this innovative vaccine strategy.
Who could benefit from this research
Good fit: Ideal candidates for participation would include individuals at high risk for HIV infection or those living with HIV who are seeking new treatment options.
Not a fit: Patients who are not at risk for HIV or those who have already achieved viral suppression with existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine against HIV-1, potentially reducing the incidence of HIV infections.
How similar studies have performed: While there have been various approaches to HIV vaccine development, this specific strategy targeting the MPER region is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Kim, Mikyung — Dana-Farber Cancer Inst
- Study coordinator: Kim, Mikyung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.